Background/Objectives: Vulvar disease leads to significant disease burden and reduced quality of life (QOL). However, vulvar disease-specific instruments to measure QOL are lacking. We developed the Vulvar Quality of Life Index (VQLI) to comprehensively and reproducibly assess symptomatic, psychosexual and physical aspects of vulvar disease.
INTRODUCTION
Skin disease of all types has a profound impact on the quality of life of patients. [1] [2] [3] There are a number of quality of life (QOL) instruments available that measure disease burden in skin disease, including the Dermatology Life Quality Index, 4 Skindex-29 and Skindex-15, 5 and the Dermatology Quality of Life Scales (DQLS). 6 However, none of these capture the nuances of specific dermatologic disease. For this reason, a number of tools are available to measure the quality of life in specific conditions, such as psoriasis, 7 acne 8 and hand eczema. 9 Although vulvar disease principally involves the skin, the unique impact of it is not fully assessed by current dermatology QOL tools, and consequently, studies examining vulvodynia 10, 11 or genital psoriasis 12 have used a combination of scores assessing sexual function, anxiety and quality of life.
There are a number of vulvar-specific QOL instruments for patients with vulvar cancer, such as the vulvar intraepithelial neoplasia questionnaire (VIN-Q), 13 the Functional Assessment of Cancer-Vulvar (FACT-V) 14 and the Sexual Function Changes Questionnaire (SVQ), 15 and there are also questionnaires available that assess sexual function, including the Female Sexual Distress Scale (FSDS), 16 the Female Sexual Function Index (FSFI) 17 and the Sexual Function and Satisfaction measure (SexFS v1.0 and v2.0). 18 However, vulvar-specific QOL instruments that assess more than sexual function or vulvar cancer are lacking. 19 A more recent QOL tool has been developed to assess vulvar disease, but on average takes more than 30 min to complete, 20 and therefore may be impractical in a clinical setting.
Therefore, a time-efficient vulvar QOL index, incorporating physical, psychosocial and sexual aspects of vulvar disease, was developed. This could be used to assess the burden of vulvar disease and to measure the effectiveness of interventions.
The objective of this study was to firstly develop a validated vulvar-specific instrument that comprehensively and reproductively assessed all aspects of vulvar disease, called the vulvar quality of life index (VQLI). Once developed, the instrument was validated in a further cohort of patients correlating the total VQLI score with an overall global score, determined by a single question self-determined Likert score, on how vulvar disease had impacted their overall health.
METHODS

Study design
A prospective cohort study was used in a group of women with vulvar disease and a cohort without vulvar disease as a control group.
Study setting and participants
Study participants were recruited from the private rooms of authors' dermatogynecology practice and from Royal North Shore Hospital, a 600-bed tertiary hospital in Sydney with outpatient speciality clinics in vulvar disease. All patients attending clinics were invited to participate.
Ethics statement
Ethics was approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC) LNR/ 16/HAWKE/103.
Participants and study size
Women aged over 18 years presenting with vulvar disease were eligible for inclusion and invited to participate in the study, which ran from March 2016 to September 2018.
In total, 475 women participated in the study (see Fig. 1 ).
Variables
Demographic and diagnostic information was collected on study participants, including age, diagnosis, sexual activity, menopause status, relationship status, treatments, children and the duration of their symptoms.
Data sources/measurement
The design of the VQLI involved four phases, including the design and development of the VQLI inferred by literature reviews and initial patient interviews, pretesting, and finally field-testing. Following field-testing and survey validation, the survey was tested on a further cohort of women validating their total VQLI score with a global score of how their vulvar disease impacted on their overall health.
Phase 1: Generation of domains and items
A comprehensive review of the literature review was undertaken on databases MEDLINE and PubMed to identify relevant themes to be included in the questionnaire. Additional relevant studies which were identified in citations in the reviewed articles were also included. Two vulvar specialists appraised the selected articles and provided consensus for inclusion.
A focus group comprising a cohort of 45 women with a diverse range of vulvar diseases, mean age 57 (range, 24 to 88), were asked to 'write down all of the ways your vulvar disease affects you.' The interviewer then asked further questions based on written responses to further understand their experience, and to further explore the impact of their vulvar disease.
From these initial interviews, extensive literature review and expert consensus from senior clinicians in the study group, seven domains were generated, with 15 items pertaining to patient symptoms, feelings and emotions relating to their vulvar disease, the impact on their activities of daily living, impacts on relationships, sexual function and concerns about their future and treatments (see Appendix S1).
The questionnaire specifically mentioned vulvar disease in each question to prompt the women to reflect on the symptoms, feeling and experience of vulvar disease, rather than unrelated dermatological comorbidities. A clinical psychologist reviewed the questions relating to anxiety and depression. 
Phase 2: Pilot testing of the initial VQLI
A pilot questionnaire was tested on a new cohort of 20 women with vulvar disease. Patients completed the questionnaire and were able to ask questions to clarify any misunderstandings. Minor changes were made to the wording of the questions to improve clarity and understanding. The revised questions were tested on a further 10 women, to ensure the questions were easily interpretable and understood. The final questions comprised a total of 15 questions, under the following domains: Symptoms (Questions 1-2); Feelings and Emotions (Questions 3-5); Activities of daily living (Questions 6-10); Relationships (Question 11); Sexual function (Questions 12-13); Future health concerns (Question 14); and Treatment (Question 15). Each of the questions was graded one to four on a Likert scale, with 0 representing no symptom or complaint ('Not at all' or 'Not applicable'), 1 'A little', 2 'A lot' and 3 'Very much', resulting in a maximum score of 45/45 and a minimum score of 0/45 (see Appendix S1).
Phase 3: Testing VQLI
The VQLI was field tested on 243 women with a range of vulvar diseases (Table 1) , and there was a 96% response rate. Patients completed a booklet containing validated questionnaires including the Dermatology Quality of Life Index (DLQI), 4 Hospital Anxiety and Depression Score (HDAS) 21 and the Female Sexual Distress Scale (FSDS) 16 were undertaken to assess the areas of mental health, dermatology and sexual function, and enable comparison to the VQLI.
A second field test of the VQLI was test-retested on 25% of the total cohort. This group completed the VQLI and were asked to complete a second VQLI one week later. These women were invited when they returned for follow-up to the clinics over a three-month period. They received a prepaid stamped envelope to return the survey, and 62/114 (54%) responded within the appropriate timeframe.
A control group of 86 women aged 21 to 70 years without a history of vulvar disease also completed the VQLI.
Phase 4: Further validation of the VQLI
The VQLI was further tested on a cohort of 157 women with vulvar disease over 179 clinic visits. These women were also provided a final question, asking how their vulvar disease impacted their overall health, with the same Likert scale used.
Statistical methods
Data were analysed using SPSS for Windows version 19 (SPSS Science, Chicago, IL, USA). Continuous variables were summarised using means and standard deviations, and categorical variables were summarised using frequencies and percentages. Crohnbach's alpha was used to assess internal consistency and test-retest to assess reliability and repeatability. The level of agreement between individual questions was assessed by quadratic weighted kappa (values 0.4-0.6 reasonable agreement, 0.61-0.8 substantial agreement). 22 The intraclass correlation coefficient (ICC) was used to assess the reliability of the overall VQLI score between the two administrations.
The relationship between each item on the VQLI and the impact that vulvar disease had on overall health was determined using a Spearman correlation. The relationship between total VQLI score and the impact that vulvar disease had on their overall health was determined using a multivariable linear mixed model, adjusting for the effect of age, diagnosis and visit. The mixed model was used to take into account multiple visits per woman.
RESULTS
In the phase 3 testing, 243/252 women (96%) completed the VQLI booklet, mean age 49 years (range, 18 to 86 years). The most common diagnosis in the field test cohort was lichen sclerosis (39.1%) followed by recurrent vulvovaginal candidiasis (17.3%). In phase 4 testing, the commonest diagnosis was lichen sclerosis (32.5%) followed by lichen planus (23.6%) ( Table 1) . 
VQLI
Patients with vulvodynia had the highest VQLI scores, (mean VQLI 20.3, standard deviation 11.5). Women on the first presentation who were yet to receive a diagnosis or treatment also had higher scores on the VQLI (18.1, range 3 to 39).
Control group
72% of the invited control group completed the VQLI questionnaire, preceded by a question 'Do you currently suffer from vulvar disease?'. Only patients who answered no were included in the group. The mean score of the control group was 1.3/45 (range 0 to 10), compared with the mean score of the whole vulvar disease cohort of 15.2/45 (range 0 to 45), P < 0.001.
Test-retest
Sixty-two of 114 (54%) of the invited women responded to the invitation to participate in the second questionnaire, for test-retest, which was 25% of the total cohort. There were a wide range of VQLI scores within the cohort ranging from 0 to 39, which reflected the random selection of patients, range of diagnoses and the range and duration of symptoms. The VQLI remained stable between 0 and day 7 results (mean score 10.7 and 9.4, respectively). The reliability result measured by quadratic weighted kappa ranged from 0.4 to 0.81 (mean 0.55). Nine of 15 questions showed levels of reliability above 0.5, and none below 0.4. The lowest level of agreement was question 3 'Over the last month how embarrassed or self-conscious have you been because of your vulvar skin symptoms?' (j = 0.4), and question 4 'Over the last month how much has your vulvar skin impacted your body image or sense of self ? (for instance femininity, feeling isolated, feeling different)' (j = 0.42). The best level of agreement was with question 1, 'Over the past month, how itchy and/or, painful and/or stinging and/or burning has your vulvar skin been?' (j = 0.81). There was a high degree of internal consistency as tested with Crohnbach's alpha (0.93) and intraclass correlation coefficient being 0.88, confidence interval 0.8 to 0.93. Additionally, there was a statistically significant correlation between the VQLI themes and other questionnaires with positive Spearman correlations; questions 3 to 5 correlated with the HADS-anxiety score (r = 0.37), HADS-depression score (r = 0.27) and questions 13 to 15 on relationships and sexual intercourse were strongly correlated with FSDS (r = 0.66). The total VQLI strongly correlated with the total DLQI score (0.89).
Phase 4 testing
In the final phase of testing, the VQLI was administered to 157 women over 179 visits, and they were asked to answer a final question as to how their vulvar disease impacted on their overall health. In this cohort, the average age of first visit was 51.4 years. The average total VQLI score was 17.7. The most common diagnosis was lichen sclerosus (32.5%), followed by recurrent vulvovaginal candidiasis (24.8%) and lichen planus (23.6%) ( Table 1 ). Most women found that their vulvar disease affected their overall health, with 54.8% of women reporting that it affected their overall health either a lot (29.3%) or very much (25.5%). The average total VQLI score was higher among women who reported that vulvar disease affected their overall health to a greater extent. The average total score was 4.0 among women whose vulvar disease did not affect their overall health, and 27.2 among women whose vulvar disease affected their overall health very much (Fig. 2) . Individual items on the VQLI scale correlated differently with the extent to which vulvar disease affected overall health. Q5 and Q6 were the most highly correlated with overall health (r = 0.61 and r = 0.58, respectively). Average scores were lowest for Q8 and Q9, and highest for Q1 and Q14 ( Table 2) . A linear mixed-model analysis shows that total VQLI score is significantly associated with the effect of vulvar disease on overall health (multivariate Pvalue < 0.001) ( Table 3 ). Women whose vulvar disease affects their overall health not at all, a little or a lot have significantly lower total VQLI scores than women whose vulvar disease affects their overall health very much. There was also a significant effect of age on total VQLI score (P = 0.032), with older women having lower total VQLI scores. There was no significant effect of diagnosis at first visit on total VQLI score.
DISCUSSION
Diseases of the vulva significantly impact patient QOL 12, 13, 23 . However, current QOL assessment for disease of the vulva involves several separate scales which is arduous, 20 making use in a busy clinic impractical. They are also limited in their scope, for instance focusing only on sexual function, 16, 24 or certain conditions, such as vulvar cancer. 13, 14, 18 This has previously limited research in vulvar disease. 10, 25 A vulvar-specific QOL tool will not only be useful in clinical practice to routinely monitor the symptoms of patients and the effectiveness of treatment, but will also provide a tool that can bring consistency to future research studies in vulvar disease. The instrument has proved easy to understand and can be completed in less than five minutes.
The VQLI captures specific data relevant to vulvar disease, information that might not otherwise be forthcoming in a consultation, due to embarrassment, time pressures or not being specifically asked about the domains. The VQLI has been validated in normal subjects, and a cohort of patients with vulvar disease has demonstrated test-retest reliability and has demonstrated high reliability correlations for individual questions. Additionally, the VQLI was tested on 157 women and was shown to correlate with the impact they felt their vulvar disease had on their overall health. The VQLI also addresses adherence, which is a major factor in chronic dermatological prognosis, with previous studies showing almost a third of patients are non-compliant 26 .
Whilst the test-retest response was lower than anticipated, further testing on a cohort of women suggests that the VQLI is a valid and reliable tool that assesses the QOL in women with vulvar disease.
The VQLI scores were lower in older women. Possible reasons include that the commonest condition in that age group was lichen sclerosis, and in younger women recurrent vulvar candidiasis, which is more symptomatic than lichen sclerosus. Additionally, older women may be less sexually active and more philosophical about accepting chronic disease. There may also have been selection bias.
We acknowledge there were limitations in our research; woman who repeated the questionnaire one week later may have had recall bias. There may have been selection bias as the women were seen by vulvar specialists or in a tertiary setting where case presentations may be more severe, and the cohort of patients seen in Sydney Australia may not be generalisable to other countries. Interviewer bias during the initial interview was minimised by ensuring that the interviewers allowed the patients to speak in their own words, without suggesting answers.
In conclusion, the VQLI is an easy-to-understand 15-item questionnaire that can readily be completed in clinic in under five minutes to assess the disease burden and impact of vulvar disease on QOL and will bring a standard for monitoring disease and measuring outcomes in a research setting for future studies.
